Cargando…
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy. Since the Food and Drug Administration approved two CD19-CAR-T products for cli...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538902/ https://www.ncbi.nlm.nih.gov/pubmed/37358555 http://dx.doi.org/10.1097/CM9.0000000000002549 |